-

iBlend.com Domain Acquired by Cabbacis

NIAGARA FALLS, N.Y.--(BUSINESS WIRE)--Cabbacis (the "Company"), a U.S. federally-licensed tobacco product manufacturer and plant biotech company focused on harm reduction products, announced today that it has purchased the www.iBlend.com domain to feature the iBlend™ brand.

The iBlend.com domain has been anonymously pursued by Cabbacis for about one year and the Company recently purchased the domain for $18,000. Tobacco products being developed under the iBlend™ brand comprise predominately of reduced nicotine tobacco and are blended with hemp, and the iBlend.com domain will be utilized for these blended tobacco products.

"The iBlend trademark has been filed and registered worldwide, and the acquisition of the iBlend.com domain greatly compliments our brand and international trademark coverage," stated Joseph Pandolfino, the Company’s CEO. Cabbacis had previously acquired various other "iBlend" domains such as iBlend.net and iBlend.org.

About Cabbacis

Cabbacis is a tobacco product manufacturer and plant biotechnology company committed to developing and commercializing reduced nicotine cigarettes and vaporizer pods. Both types of products in development are predominately tobacco and include hemp. The Company stands ready to also move forward with reduced nicotine tobacco cigarettes without hemp.

Reduced nicotine cigarettes without hemp have been evaluated in dozens of independent studies and contain about 95 percent less nicotine than conventional cigarettes. Results demonstrate that subjects smoked fewer cigarettes per day, reduced their nicotine dependence and exposure, doubled their quit attempts, and/or increased their number of smoke-free days. The Company believes including hemp flower into reduced nicotine cigarettes improves sensory characteristics and the Company expects effectiveness to also improve due to the presence of non-THC cannabinoids.

The Company’s worldwide patent portfolio includes 31 issued patents and various pending patent applications across the United States, Europe, China, Japan, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other countries — where approximately two-thirds of the world’s smokers reside. The Company holds 6 U.S. patents. Cabbacis Inc wholly owns Cabbacis LLC.

To learn more about Cabbacis, please visit www.cabbacis.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "foresee," "intend," "likely," "may," "objective," "plan," "potential," "plan," "predict," "project," "seek," "should," "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in "Risk Factors" in our Regulation A Offering Circular filed with the SEC and, when filed, our Annual Report on Form 1-K for the period ended December 31, 2023. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.

Contacts

Media
Tracy Witman
support@cabbacis.com

Cabbacis


Release Summary
Cabbacis purchased the www.iBlend.com domain to feature the iBlend™ brand of tobacco products being developed by the Company.
Release Versions

Contacts

Media
Tracy Witman
support@cabbacis.com

More News From Cabbacis

Cabbacis Reports First Half 2026 Financial Results and Provides Corporate Update

NIAGARA FALLS, N.Y.--(BUSINESS WIRE)--Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on risk-reduction products being developed under the iBLEND™ and X95™ brand names, today announced that it has filed its Semiannual Report on Form 1-SA for the six-month period ending June 30, 2026 with the U.S. Securities and Exchange Commission (the “SEC”). First Half 2026 Financial Results and Company Highlights The Company’s net loss in the first half of 2026 was $1,3...

Cabbacis Files “X95” Worldwide Trademark Applications for Very-Low-Nicotine Cigarette Brand

NIAGARA FALLS, N.Y.--(BUSINESS WIRE)--Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on risk-reduction products being developed under the iBLEND™ and X95™ brand names, today announced that it has filed worldwide trademark applications for its X95™ cigarette brand. X95 is a patent-pending, very-low-nicotine, tobacco cigarette without any hemp and contains approximately 95 percent less nicotine than commercial cigarette brands. Cabbacis has filed trademark...

Cabbacis to Participate in the Moody Capital Disruptive Growth & Life Sciences Conference

NIAGARA FALLS, N.Y.--(BUSINESS WIRE)--Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on risk-reduction products being developed under the iBLEND™ and X95™ brand names, today announced that management will participate in the Moody Capital Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Joseph Pandolfino, Chief Executive Officer of Cabbacis, is scheduled to deliver a corporate presentation and host one-...
Back to Newsroom